HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eplerenone: a selective aldosterone receptor antagonist (SARA).

Abstract
Aldosterone, the final product of the renin-angiotensin-aldosterone system (RAAS), is a mineralocorticoid hormone that classically acts, via the mineralocorticoid (aldosterone) receptor, on epithelia of the kidneys, colon, and sweat glands to maintain electrolyte homeostasis. Aldosterone has also been shown to act at nonepithelial sites where it can contribute to cardiovascular disease such as hypertension, stroke, malignant nephrosclerosis, cardiac fibrosis, ventricular hypertrophy, and myocardial necrosis. Although angiotensin-converting enzyme (ACE) inhibitors and angiotensin type 1 (AT(1)) receptor antagonists act to suppress the RAAS, these agents do not adequately control plasma aldosterone levels--a phenomenon termed "aldosterone synthesis escape." Spironolactone, a nonselective aldosterone receptor antagonist, is an effective agent to suppress the actions of aldosterone; its use is, however, associated with progestational and antiandrogenic side effects due to its promiscuous binding to other steroid receptors. For these reasons, eplerenone--the first agent of a new class of drugs known as the selective aldosterone receptor antagonists (SARAs)--is under development. In rodent models, eplerenone provides marked protection against vascular injury in the kidney and heart. In phase II clinical trials, eplerenone demonstrates 24-h control of blood pressure with once or twice daily dosing, and is safe and well tolerated in patients with heart failure when given with standard of care agents. Pharmacokinetic studies reveal that eplerenone has good bioavailability with low protein binding, good plasma exposure, and is highly metabolized to inactive metabolites and excreted principally in the bile. Eplerenone is well tolerated in acute and chronic safety pharmacology studies. Ongoing phase III trials of eplerenone in the treatment of hypertension and heart failure are underway. These studies will extend our understanding of selective aldosterone receptor antagonism in the treatment of chronic cardiovascular disease.
AuthorsJ A Delyani, R Rocha, C S Cook, D S Tobert, S Levin, B Roniker, D L Workman, Y L Sing, B Whelihan
JournalCardiovascular drug reviews (Cardiovasc Drug Rev) Vol. 19 Issue 3 Pg. 185-200 ( 2001) ISSN: 0897-5957 [Print] United States
PMID11607037 (Publication Type: Journal Article, Review)
Chemical References
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
  • Eplerenone
Topics
  • Animals
  • Clinical Trials as Topic
  • Eplerenone
  • Heart Failure (drug therapy)
  • Humans
  • Hypertension (drug therapy)
  • Mineralocorticoid Receptor Antagonists (chemistry, pharmacokinetics, pharmacology, therapeutic use, toxicity)
  • Spironolactone (analogs & derivatives, chemistry, pharmacokinetics, pharmacology, therapeutic use, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: